Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse

Area of Science:

• Hematology
• Oncology
• Transplantation immunology

Background:

• Acute nonlymphoblastic leukemia (ANLL) relapse presents treatment challenges.
• Allogeneic marrow transplantation is a potential curative option for ANLL.
• Timing of transplantation relative to remission status is critical.

Purpose of the Study:

• To evaluate the impact of pre-transplant remission induction attempts on outcomes of allogeneic marrow transplantation in ANLL.
• To determine the optimal timing for marrow transplantation in ANLL patients experiencing first relapse.

Main Methods:

• Retrospective analysis of 62 ANLL patients undergoing HLA-matched sibling marrow transplantation.
• Patients categorized into three groups based on pre-transplant remission status: no reinduction, failed reinduction, and achieved reinduction.
• Comparison of disease-free survival, nonleukemic mortality, and leukemia recurrence rates.

Main Results:

• Disease-free survival rates were 29% (no reinduction), 10% (failed reinduction), and 20% (achieved reinduction).
• Patients transplanted without reinduction attempts (Group 1) had a lower risk of leukemia recurrence.
• Early relapse ( <30% blasts) showed better outcomes than florid relapse.

Conclusions:

• Allogeneic marrow transplantation without prior reinduction attempts in ANLL first relapse yields comparable or superior results to transplantation in second remission.
• Transplanting ANLL patients as soon as possible after the first relapse is recommended.